-
Anne Wojcicki: the daring 23andMe CEO who reached too far
Profile Anne Wojcicki dreamed of a revolution in personal genomics and medicine and set up 23andMe in 2006. Its collapse into bankruptcy provides a cautionary tale
Profile -
Cash in on the biotech sector with specialist BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
Opinion -
How to invest in weight-loss drugs
The new generation of weight-loss drugs are a boon for the overweight, but they also promise to change our relationship with food and revolutionise the economy
-
Vertex Pharmaceuticals is a rare opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Investment opportunities in supporting an ageing population
Ageing populations have prompted fruitful research in sectors ranging from pharmaceuticals and medical equipment to glasses and hearing aids
-
AstraZeneca goes cheap – should you buy?
The decline in AstraZeneca’s share price is overdone given the outlook, and the stock is cheap
-
Vaccine maker shares slump after Trump picks RFK Jr as next US health secretary
Drugmakers' shares slumped after RFK Jr, a vaccine sceptic, was appointed as the next US Health Secretary. How will this affect drug companies?
-
Investing in pharmaceutical companies? The pipeline is key
A strong pipeline is all-important for pharmaceutical companies. We highlight the most interesting candidates.
-
The battle against heart disease and how to invest in it
Heart disease is soaring due to rising obesity and an ageing population. But new drugs, treatments and diagnostic tools are on the way.
